Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.

International journal of clinical oncology 2022 Mar

filter terms:

Therapy of patients with relapsed and refractory classic Hodgkin lymphoma (r/r cHL) after PD-1 inhibitors failure remains an unresolved issue. The aim of this study was to evaluate the efficacy and safety of the combination of nivolumab with brentuximab vedotin (Nivo + BV) after nivolumab monotherapy failure. This study retrospectively analyzed 21 patients with r/r cHL who were treated with the combination of Nivo + BV after Nivo failure. The response was evaluated by PET-CT scan according to the LYRIC criteria. Adverse events (AEs) were assessed according to NCI CTCAE v.4.03. Median follow-up was 19 (9-47) months. The ORR was 57%. The median OS was not reached, 24 month OS was 80% (95% CI 50-93%). Median PFS was 12 months with 24 month PFS of 31% (95% CI 12-53%). Any grade AEs were observed in 12 patients (63%), 3-4 grade AEs in 2 patients (10%). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after Nivo + BV was performed in 8 (38%) patients. The median time between Nivo + BV and allo-HSCT was 8 (5-21) months. Combination of Nivo + BV in r/r cHL after nivolumab monotherapy failure is potentially an effective and safe approach. © 2021. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Citation

Liudmila V Fedorova, Kirill V Lepik, Nikita P Volkov, Polina V Kotselyabina, Evgenia S Borzenkova, Marina O Popova, Anastasia V Beynarovich, Vadim V Baykov, Andrey V Kozlov, Ivan S Moiseev, Natalia B Mikhailova, Alexander D Kulagin. Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma. International journal of clinical oncology. 2022 Mar;27(3):626-632